


Beyond RA: Navigating Biologics Across the SpA Spectrum



PsA Clinical Trial Efficacy		
Trial	Drug	Key Outcome
DISCOVER-1/2	Guselkumab (IL-23)	Significant improvement: joints, skin (PASI), enthesitis
COSMOS	Guselkumab (IL-23)	Proven efficacy: previous anti-TNF failures
SELECT-PxA	Upadacitinib (JAKi)	Strong efficacy: incl. anti-TNF inadequate responders

